Dragonfly Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
35 Gatehouse Dr, Waltham, Massachusetts,...Phone Number
(617) 588-0086Website
www.dragonflytx.comRevenue
$8.4 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
2
About Dragonfly Therapeutics
Dragonfly Therapeutics, Inc. is focused on developing novel B & T cell depleters to address critical autoimmune targets for diseases with high unmet need. The company aims to revolutionize disease treatment through advanced immunotherapies, collaborating with major pharmaceutical partners like AbbVie, BMS, Gilead, and Merck. Their pipeline includes drug candidates targeting autoimmune diseases, oncology, fibrosis, and neuro-inflammation. Dragonfly is committed to growing its pipeline to improve patient outcomes in various therapeutic areas.Explore more
Dragonfly Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dragonfly Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Dragonfly Therapeutics recently announced quarterly report
Click to see if Dragonfly Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Dragonfly Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Dragonfly Therapeutics has new funding data
Check out if Dragonfly Therapeutics is spiking on competitors!
Product Launch: Get notified when Dragonfly Therapeutics launches new products
Check if Dragonfly Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Dragonfly Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Dragonfly Therapeutics
Find more new buyers
Compare Similar Companies to Dragonfly Therapeutics
Compare insights from companies similar to Dragonfly Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dragonfly Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dragonfly Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dragonfly Therapeutics.
Dragonfly Therapeutics Tech Stack
A closer look at the technologies used by Dragonfly Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Project
Spending/Investment
Project
Spending/Investment
Award
Award, Employee Engagement, Compensation & Benefits, Employee Relations, Company Culture & Policy, HR Operations
Dragonfly Therapeutics News & Media
Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
DF9001 is currently being evaluated as a monotherapy for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. The clinical trial collaboration will focus on evaluating the investigational combination in second line Renal Cell...Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
DF9001 is currently being evaluated as a monotherapy for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. The clinical trial collaboration will focus on evaluating the investigational combination in second line Renal Cell...Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials. WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt...Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials. WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dragonfly Therapeutics
Sign Up For FreeTo access detailed company insights
Dragonfly Therapeutics, Inc. is focused on developing novel B & T cell depleters to address critical autoimmune targets for diseases with high unmet need. The company aims to revolutionize disease treatment through advanced immunotherapies, collaborating with major pharmaceutical partners like AbbVie, BMS, Gilead, and Merck. Their pipeline includes... Read More
